EHealth: Individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 9, 2012, Pages 840-849

  Pedersen, N ^a   Elkjaer, M ^b   Duricova, D ^c   Burisch, J ^a   Dobrzanski, C ^a   Andersen, N N ^a   Jess, T ^d   Bendtsen, F ^e   Langholz, E ^a   Leotta, S ^b   Knudsen, T ^f   Thorsgaard, N ^g   Munkholm, P ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Elsinore Hospital   (Denmark)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Statens Serum Institute   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f University of Esbjerg   (Denmark)

^g HERNING HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; CALGRANULIN; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE;

ABDOMINAL MASS; ABDOMINAL PAIN; ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULITIS; HEALTH CARE COST; HUMAN; INFUSION RELATED REACTION; INTERNET; LOOSE FECES; MAINTENANCE CHEMOTHERAPY; MALE; ONLINE SYSTEM; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; SCORING SYSTEM; SHORT FORM 36; SOCIAL STATUS; TELEMEDICINE; URTICARIA; WELLBEING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DENMARK; FEMALE; GASTROINTESTINAL AGENTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNET; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PILOT PROJECTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SELF ADMINISTRATION; SELF CARE; SEVERITY OF ILLNESS INDEX; TELEMEDICINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878588408     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12043     Document Type: Article

References (40)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
2. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13. (Pubitemid 38182297)
3. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-42. (Pubitemid 43261469)
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85. (Pubitemid 38252535)
5. Pedersen N, Duricova D, Lenicek M, et al. Infliximab dependency is related to decreased sur-gical rates in adult Crohn's disease patients. Eur J Gastroenterol Hepatol 2010; 22: 1196-203.
6. Duricova D, Pedersen N, Lenicek M, et al. Infliximab dependency in children with Crohn's disease. Aliment Pharmacol Ther 2009; 29: 792-9.
7. Cross R, Quezada S. Telemedicine for chronic digestive diseases: a systematic qualitative review. In: Graschew G, Rakowsky S, eds. Telemedicine. Techniques and Applications. Rijeka, Croatia: InTech, 2011; 347-62.
8. COCIR: European Coordination Committee of the Radiological, Electro medical and Health-care IT Industry, Telemedicine toolkit, February 2010. Available at: http://www.cocir.org/uploads/documents/eHealth%20Toolkit%20LINK2. pdf. Accessed September 4, 2012.
9. Commission of the European Communities, Brussels, 4.11.2008, COM (2008) 689, final communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on telemedicine for the benefit of patients, healthcare systems and society. 2008. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do? uri=COM:2008:0689:FIN:EN:PDF. Accessed September 4, 2012.
10. FDA Clears Wireless ViSi(R) Mobile Patient Monitoring System Aimed at Enhancing Patient Safety for Ambulatory Hospital Patients. September 3, 2012. NewsRX. Medical News Article. Available at: http://www.newsrx.com/health- articles/3243361.html.
11. Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut 2010; 59: 1652-61.
12. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997; 44: 287-302. (Pubitemid 27293419)
13. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and de-pendency in Crohn's disease. Gut 1994; 35: 360-2.
14. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
15. Elkjaer M, Burisch J, Avnstrom S, et al. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol 2010; 22: 695-704.
16. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53. (Pubitemid 43764536)
17. Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006; 12: 304-10.
18. Elkjaer M, Burisch J, Voxen HV, et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther 2010; 31: 323-30.
19. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212.
20. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996; 91: 1571-8. (Pubitemid 26269173)
21. McHorney CA, Ware JE Jr. Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63.
22. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009; 15: 1105-18.
23. Eaden JA, Abrams K, Mayberry JF. The Crohn's and Colitis Knowledge Score: a test for measuring patient knowledge in inflammatory bowel disease. Am J Gastroenterol 1999; 94: 3560-6.
24. Reilly MC, Gerlier L, Brabant Y, et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008; 30: 393-404. (Pubitemid 351474386)
25. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009; 44: 774-81.
26. Evangelista LS, Stromberg A, Westlake C, et al. Developing a Web-based education and counseling program for heart failure patients. Prog Cardiovasc Nurs 2006; 21: 196-201.
27. Kelly JJ, Sweigard KW, Shields K, et al. John M. Eisenberg Patient Safety Awards. Safety, effectiveness, and efficiency: a Web-based virtual anticoagulation clinic. Jt Comm J Qual Saf 2003; 29: 646-51.
28. Taitel MS, Kotses H, Bernstein IL, et al. A self-management program for adult asthma. Part II: cost-benefit analysis. J Allergy Clin Immunol 1995; 95: 672-6.
29. Robinson A. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001; 358: 976-81. (Pubitemid 32913524)
30. Cross RK, Finkelstein J. Feasibility and acceptance of a home telemanagement system in pa-tients with inflammatory bowel disease: a 6-month pilot study. Dig Dis Sci 2007; 52: 357-64. (Pubitemid 46202806)
31. Cross RK, Cheevers N, Rustgi A, et al. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis 2011; 18: 1018-25.
32. Krier M, Kaltenbach T, McQuaid K, et al. Potential use of telemedicine to provide outpatient care for inflammatory bowel disease. Am J Gastroenterol 2011; 106: 2063-7.
33. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination ther-apy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
34. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6: 1212-7.
35. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of in-fliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-8.
36. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73. (Pubitemid 46454266)
37. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiol-ogy, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 51-8.
38. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54. (Pubitemid 44512213)
39. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
40. Vande Casteele N, Compernolle G, Ballet V. OP11 Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled trough level adapted infliximab treatment (TAXIT) trial. JCC Suppl OP 2012; 6(Suppl. 1): S6.